Endometriosis Management: Hormonal Therapy and Surgical Decision-Making
Sam Anderson
Diagnosis: Clinical Suspicion and Imaging
Endometriosis is a chronic inflammatory condition that affects a significant proportion of reproductive-age women yet remains underdiagnosed — with an average delay from symptom onset to diagnosis that can span years. For the gynecologist, reproductive endocrinologist, or primary care physician evaluating a patient with pelvic pain, dysmenorrhea, or infertility, having a systematic approach to diagnosis and a clear understanding of when to pursue hormonal therapy versus surgical intervention is essential for reducing the diagnostic delay and optimizing outcomes.
Endometriosis should be suspected in any woman with cyclic or chronic pelvic pain, dysmenorrhea unresponsive to NSAIDs, dyspareunia, or subfertility. Transvaginal ultrasound (TVUS) with expert sonography detects endometriomas with sensitivity of 93% and deep infiltrating endometriosis (DIE) with sensitivity of 79-94%[3] using the International Deep Endometriosis Analysis (IDEA) group standardized approach. MRI provides complementary information for retrocervical, uterosacral, and bowel endometriosis (sensitivity 90%, specificity 91%). Laparoscopy is no longer required for diagnosis per the ESHRE 2022 guideline update; empiric treatment based on clinical suspicion and imaging is now recommended as first-line.
First-Line Hormonal Therapy
Combined oral contraceptives (continuous regimen preferred) reduce dysmenorrhea in approximately 60-80% of patients and are recommended as first-line medical therapy. Progestins represent the primary evidence-based alternative: dienogest 2 mg daily demonstrated a 5-point reduction on the VAS pain scale (from 6.4 to 1.5) at 24 weeks in the pivotal phase 3 trial[1]. Norethindrone acetate 5 mg daily and the levonorgestrel IUD (52 mg) are effective alternatives with different side effect profiles. The levonorgestrel IUD reduces endometriosis-associated pain with a mean VAS reduction of 4.2 points at 6 months, with the added advantage of contraception and fewer systemic progestogenic side effects.
Second-Line Medical Therapy: GnRH Antagonists
Oral GnRH antagonists have transformed second-line endometriosis management. Elagolix (150 mg daily for non-menstrual pain, 200 mg twice daily for dysmenorrhea) reduced dysmenorrhea by 46-76% versus placebo in the ELARIS EM-I/II trials[2]. Relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg daily) provides estrogen add-back within the same tablet, maintaining BMD (see bone health in premenopausal women) while achieving pain reduction comparable to GnRH agonist depot injections. The SPIRIT trials demonstrated that 24 weeks of relugolix CT reduced dysmenorrhea VAS scores by 63% versus 28% for placebo, with less than 1% mean BMD loss at the lumbar spine[3].
Surgical Decision-Making: When and How
Surgery is indicated for refractory pain after adequate medical therapy (typically 3-6 months), large endometriomas (above 4 cm or symptomatic), bowel or ureteral obstruction, and infertility with associated endometriomas. Laparoscopic excision is preferred over ablation for deep infiltrating endometriosis based on the randomized trial by Healey et al. showing lower pain recurrence at 5 years (27% versus 57%, p=0.004). For endometriomas, the ESHRE guidelines recommend cystectomy over drainage and ablation for improved fertility outcomes (spontaneous pregnancy rate 54% versus 23% at 12 months in the Cochrane meta-analysis)[5].
Endometriosis and Fertility
Endometriosis is identified in 25-50% of infertile women (patients with concurrent PCOS may have overlapping anovulatory infertility). The EFI (Endometriosis Fertility Index) score at surgery predicts non-IVF pregnancy rates and guides post-surgical management. For mild-moderate disease (rASRM stage I-II), the Canadian ENDOCAN trial showed controlled ovarian stimulation plus IUI increased pregnancy rates from 4% to 15% per cycle versus expectant management. For moderate-severe disease or after failed conservative surgery, IVF achieves live birth rates of 40-50% per cycle, comparable to non-endometriosis IVF outcomes. Prolonged GnRH agonist suppression (2-3 months) before IVF improves live birth rates by an OR of 4.28 (95% CI 2.00-9.15) per the Cochrane analysis[4].
The Pain-Versus-Fertility Tension
The most challenging clinical conversations in endometriosis arise when pain management and fertility goals conflict. Hormonal therapies that effectively suppress pain — dienogest reducing VAS from 6.4 to 1.5, relugolix CT cutting dysmenorrhea by 63% — are inherently contraceptive and must be discontinued for conception. Surgery improves fertility (cystectomy achieving spontaneous pregnancy in 54% at 12 months) but carries risks of reduced ovarian reserve from endometrioma excision. For the patient who wants both pain relief now and pregnancy in the future, the treatment plan must be explicitly sequenced: hormonal suppression for symptom control, planned discontinuation when conception is desired, and a clear understanding that symptoms may return during the conception window. Pre-surgical AMH measurement helps counsel patients about the impact of endometrioma surgery on their ovarian reserve and informs the decision between surgery and proceeding directly to IVF.
Limitations and the Recurrence Reality
Even with expert excision, the 27% pain recurrence rate at 5 years means that over a quarter of surgically treated patients will need additional intervention — and ablation fares worse at 57%. This is not a failure of surgical technique but a reflection of the chronic, recurrent nature of endometriosis. Post-surgical hormonal therapy (levonorgestrel IUD or continuous OCs) reduces recurrence but does not eliminate it. The empiric treatment approach now endorsed by ESHRE — treating based on clinical suspicion without requiring laparoscopic confirmation — is efficient and avoids surgical morbidity, but it means some patients receive prolonged hormonal therapy for symptoms that may have a different underlying cause. And the deep infiltrating phenotype involving bowel or ureters demands multidisciplinary surgical expertise that many centers simply do not have, creating geographic disparities in care quality.
References
- Dienogest is a specific and novel therapeutic agent for endometriosis: a placebo-controlled, randomized, double-blind phase III trial PubMed 20444534
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist PubMed 28525302
- Relugolix Combination Therapy in Women With Endometriosis-Associated Pain: SPIRIT Long-Term Safety and Efficacy Study PubMed 35717987
- GnRH agonist pretreatment before IVF in women with endometriosis: a Cochrane review update PubMed 31747470
- Endometrioma cystectomy versus drainage and coagulation: a Cochrane systematic review and meta-analysis PubMed 39588841
Frequently Asked Questions
Is laparoscopy still required to diagnose endometriosis?
What is the most effective first-line medical therapy for endometriosis pain?
Does excision or ablation have better outcomes for deep infiltrating endometriosis?
Does GnRH agonist pretreatment before IVF improve outcomes in endometriosis?
What is relugolix combination therapy for endometriosis?
What percentage of infertile women have endometriosis?
Explore This Topic in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
Founder of Ailva.ai | Former Director of Research and Author of 200+ Medically Reviewed Articles | Editor-in-Chief of EudaLife Magazine